Quantcast

Latest Lenalidomide Stories

2010-12-07 06:00:00

MORRISTOWN, N.J. and HYDERABAD, India, Dec. 7, 2010 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) and Natco Pharma Limited (BSE: 524816) today confirmed an exclusive, U.S. development and license agreement, to develop and commercialize lenalidomide 5, 10, 15 and 25 mg tablets. The companies also confirmed that Natco has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market its lenalidomide 5, 10,...

2010-12-06 10:22:00

BURLINGTON, Mass., Dec. 6, 2010 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the continued uptake of Celgene's Revlimid in the first-line setting and the launch of several premium-priced emerging therapies will drive robust 7.2 percent annual growth through 2019 in the multiple myeloma drug market. The Pharmacor 2010 findings from the topic entitled Multiple Myeloma which will publish later...

2010-12-06 07:30:00

NEW YORK, Dec. 6, 2010 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced data presented for the first time at the 52nd Annual Meeting of the American Society of Hematology showing promising clinical activity, safety and tolerability of perifosine in patients with advanced chronic lymphocytic leukemia (CLL) and Hodgkin's lymphoma (HL). KRX-0401 (perifosine) is the Company's novel, potentially first-in-class, oral anti-cancer agent that inhibits Akt...

2010-12-06 07:30:00

In two Phase 2 studies, perifosine achieves objective responses and high rates of stable disease as a single-agent in the treatment of Chronic Lymphocytic Leukemia (CLL), and in combination with sorafenib in the treatment of relapsed/refractory Hodgkin's Lymphoma (HL) QUEBEC CITY, Dec. 6 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS,TSX: AEZ) today announced Phase 2 data presented for the first time on perifosine, its lead novel oral anti-cancer compound, showing promising...

2010-12-06 03:25:00

PALO ALTO, Calif., Dec. 6, 2010 /PRNewswire/ -- Telik, Inc. (Nasdaq: TELK) today announced positive results from a Phase 2 multicenter trial of oral ezatiostat hydrochloride (TELINTRA, TLK199) in patients with an International Prognostic System Score (IPSS) of low to intermediate-1 risk myelodysplastic syndrome (MDS). The presentation entitled Phase 2 Randomized Multicenter Study of Extended Dosing Schedules of Oral Ezatiostat HCl (Telintra), a Glutathione Analog,...

2010-11-29 14:36:45

Researchers to present 12 oral and 28 poster sessions at the premier hematology research conference The John Theurer Cancer Center at Hackensack University Medical Center announced today that it will present research updates and clinical trial results of 40 cutting-edge studies at the 52nd Annual American Society of Hematology (ASH) Meeting in Orlando from December 4 "“ 6. The presentations showcased at ASH will include 12 oral sessions and 28 poster presentations, including...

2010-09-23 08:00:00

BURLINGTON, Mass., Sept. 23 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, for the treatment of multiple myeloma, more surveyed European hematologist-oncologists consider the combination of immunomodulatory agents and proteasome inhibitors promising with respect to efficacy than is the case for any other drug regimen combinations. In light of these findings, the emerging regimen of Onyx...

2010-09-08 02:00:00

EMERYVILLE, Calif., Sept. 8 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that it has entered into an exclusive agreement with Ono Pharmaceutical Co., Ltd. to develop and commercialize two compounds from Onyx's proteasome inhibitor development program, carfilzomib and ONX 0912. Under the terms of the agreement, Ono has exclusive rights to develop and commercialize both compounds for all oncology indications in Japan. Onyx retains commercialization...

2010-07-26 06:00:00

EMERYVILLE, Calif., July 26 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced positive top-line results from the Phase 2b 003-A1 study of single-agent carfilzomib, a selective, next generation proteasome inhibitor, in patients with relapsed and refractory multiple myeloma. In an independent review of the data, carfilzomib achieved an overall response rate (partial response or greater) of 24 percent and a median duration of response of 7.4 months in...

2010-06-08 08:00:00

PALO ALTO, Calif., June 8 /PRNewswire-FirstCall/ -- Telik, Inc. (Nasdaq: TELK) today announced positive results from a Phase 2 multicenter trial of ezatiostat hydrochloride (TELINTRA, TLK199) tablets in patients with an International Prognostic System Score (IPSS) low to intermediate-1 risk myelodysplastic syndrome (MDS). The primary objective of the study was to determine the Hematologic Improvement (HI) rate according to the International Working Group criteria (IWG, 2006). Since MDS...


Word of the Day
pungle
  • To take pains; labor assiduously with little progress.
This word comes from the Spanish 'pongale,' put it.
Related